OBR and MDoutlook are pleased to share excerpts from the most recent MDoutlook’s OncoPolls™ from this year’s ASCO and EHA annual meetings. This report highlights certain presentations concerning the treatment of Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM). This research is based on separate surveys conducted for each hematologic malignancy. The full complimentary report is available through MDoutlook per details below.
Impact of ASCO/EHA Presentations on Ibrutinib Usage in CLL
Impact of ASCO/EHA Presentations on Usage of anti-CD20 Antibodies in CLL
Awareness and Expected Impact of Selected New Agents for CLL
Expected Usage of Elotuzumab Today in Relapsed / Refractory Myeloma, if Commercially Available
Expected Impact of Daratumumab for the Treatment of Relapsed Multiple Myeloma
Treatment of Relapsed MM: Kd Expected to Surpass Vd
Conclusions: Immediate Impact of 2015 ASCO & EHA Presentations on Clinical Practice for CLL & MM
For a more detailed analysis report, please click here to download the full report.
Submitted by Robert Stephan, Sr. Director Medical Services and Strategy, and Jan Heybroek, President MDoutlook.
You must be logged in to post a comment